In The News
In The News
October 27, 2020
Summary
Background
The Lung Cancer Master Protocol (Lung-MAP; S1400) is a completed biomarker-driven master protocol designed to address an unmet need for better therapies for squamous non-small-…
October 27, 2020
In the last issue issue of Targeted Therapies in Oncology, Marcus Neubauer, MD, chief medical officer for The US Oncology Network, and I kicked off a 2-part series exploring the implications of the…
October 26, 2020
Key Prominent Players Covered in the COVID-19 Diagnostics Market Research Report Are PerkinElmer Inc., Quest Diagnostics Incorporated, Quidel Corporation, Siemens Healthcare GmbH, Abbott, Thermo…
October 20, 2020
Though clinical research, in general, has been challenged during the COVID-19 pandemic, oncology trials “have several unique considerations due to disease severity, regimen complexity, and acute care…
October 20, 2020
In the 1970s, cancer survival was poor for young children and older adults in the United States, as shown by data published in the Journal of the National Cancer Institute.
Great progress has been…
October 20, 2020
NEW YORK (Reuters Health) - New findings debunk the conventional wisdom that Black cancer patients are less likely to agree to participate in clinical trials.
Overall, 55% of patients offered trial…
October 19, 2020
On a daily basis, the U.S. Food and Drug Administration is responsible for making highly complex and consequential regulatory decisions. To meet this responsibility, the FDA must have a modern…
October 15, 2020
NEW YORK, Oct. 15, 2020 /PRNewswire/ -- Aetion co-authored a study published today in Science, which examined lethal coronaviruses SARS-CoV-2, SARS-CoV-1, and MERS-CoV to identify…
October 13, 2020
Executive Summary
Stephen Hahn also said the expedited approval process could be even more efficient.
The rolling application assessment that the US Food and Drug Administration is using for…
October 11, 2020
In another era, what happened Wednesday might have been viewed simply as good news. Two companies, Regeneron Pharmaceuticals and Eli Lilly, have independently developed therapeutic drugs, called …